Navigation Links
DermTech and Rady Children's Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
Date:10/27/2008

DermTech's Non-invasive EGIR Technology to be Employed to Generate Genetic,

Objective Data on Therapy Response

LA JOLLA, Calif., Oct 27 /PRNewswire/ -- DermTech, a biotechnology company developing EGIR(TM) (Epidermal Genetic Information Retrieval) technology for the non-invasive early detection of melanoma, drug development and other applications, and Rady Children's Hospital-San Diego, today announced the initiation of a study involving the use of the company's EGIR technology as a vehicle to evaluate oral and/or topical Vitamin D as a treatment for atopic dermatitis (eczema).

"We are looking forward to working with the team at DermTech and employing the company's non-invasive EGIR ("tape stripping") technology as part of our research," said Lawrence F. Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology, Rady Children's Hospital and the Principal Investigator on the study. "Atopic dermatitis is a condition that gets little public attention but can have a major negative impact on a child or young adult's quality of life. A recent small study has suggested that Vitamin D may help bolster the skin's immune responses, but more data is needed. We will be using the EGIR technology to evaluate the expression of defense proteins in the affected population before and after treatment with Vitamin D to help elucidate a potentially important part of atopic dermatitis immunology and therapy."

Atopic dermatitis is a common, chronic inflammatory skin disease with complex immunologic features. It has 15-20% prevalence in children within the first decade of life and there are limited therapeutic options.

In "normal skin", anti-microbial peptides (AMP) such as cathelicidin (hCAP18/LL37) help regulate innate immunity by directly killing microbes including Gram-positive and Gram-negative bacteria, as well as fungi and certain viruses. Patients with atopic dermatitis however, lack sufficient expression of these AMPs and thus are susceptible to uncontrolled bacterial colonization and infection that may stimulate skin inflammation. It is postulated that topical Vitamin D may induce expression of cathelicidin and help stimulate an appropriate immune response.

"Rady Children's Hospital is widely recognized for its leading-edge research and its significant contribution to scientific leadership and the community of San Diego and beyond," said George Schwartz, CEO, DermTech. "We are very pleased to be working with Dr. Eichenfield and the researchers at Rady Children's, to provide genetic information that will correlate to the observed clinical effects of this new potential therapy for atopic dermatitis. Ideally, the results will lead to improved options for a common pediatric disease."

Using EGIR in the research setting represents a key application of this technology -- to assess patients' responsiveness to current or pipeline therapeutics at the genetic level. Specifically, DermTech's patented EGIR technology will allow researchers to use a piece of custom tape, about the size of a small round band-aid, to painlessly obtain RNA from the upper layer of skin. The RNA will be extracted from the tape and using molecular biology tools, analyzed to help determine if Vitamin D induces molecular changes leading to enhanced immunity.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens obtained from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR(TM) and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis.

For additional information visit: http://www.dermtech.com.

About Rady Children's Hospital-San Diego:

Rady Children's Hospital is a 261-bed pediatric care facility providing the largest source of comprehensive pediatric medical services in San Diego, Southern Riverside and Imperial counties. As the sole hospital in the San Diego area dedicated exclusively to pediatric healthcare, Rady Children's is the region's only designated pediatric trauma center. Rady Children's has a 54-bed Pediatric Critical Care unit and a 38-bed Neonatal Intensive care unit, along with the only comprehensive pediatric Cancer Care Center in San Diego.
For additional information visit: http://www.rchsd.org

Contacts:

DermTech

George Schwartz, CEO

858.450.4222

Jennifer Larson

415.725.2017

jlarson@dermtech.com

Rady Children's Hospital-San Diego

Ben Metcalf

858.966.8579

bmetcalf@rchsd.org


'/>"/>
SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
4. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. ABR-Affinity BioReagents to Participate in the American Association for Cancer Research Meeting in San Diego, California, April 12 - 16, 2008
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):